Boston, MA – Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) recently reported a stock transaction by its Chief Financial Officer, Mark E. Dmytruk, according to a recent SEC filing. The transaction comes as ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Therefore, the Zacks rating upgrade for Ginkgo Bioworks basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

BOSTON - Ginkgo Bioworks (NYSE: DNA), a leader in cell programming and biosecurity, has granted restricted stock units (RSUs) to employees of two recently acquired companies, Patch... BOSTON - In ...

Ginkgo Bioworks faces ongoing revenue declines and high cash burn, despite cost-cutting efforts. Find out why I maintain a ...

Ginkgo Bioworks Holdings Inc, based in Boston, Massachusetts, specializes in cell programming to revolutionize the production of various products. By manipulating cells, they create novel ...